The Study of Occult Hepatits B Virus Infection in Blood Donors Using Quantitative HBsAg Combining with HBV Profile Immunoassay
Article Sidebar
Main Article Content
Abstract
At present the occult hepatitis B infection (OBI) has been more found with the meticulous test in blood donor screening. The serological blood borne infectious test has also been improved to be more sensitive and specific for detection of hepatits B surface antigen (HBsAg). It shows both of qualitative and quantitative result which can be efficiently utilized in HBsAg blood donors screening. This study was aimed to study the hepatits B infection in blood donors using quantitative HBsAg immunoassay especially in OBI stage. The HBV DNA Nucleic acid amplification technology (NAT) reactive but HBsAg qualitative seronegative samples were collected. They were further tested with Liaison® XL MUREX HBsAg Quant and simultaneously with HBV profile. The result showed the ratio 1:733 of HBV DNA NAT reactive and HBsAg qualitative seronegative among the Northeastern donors. The HBsAg Quantitative test was performed and showed seronegative. But the HBV profile test that could identify the stage of HBV infection found both chronic or acute infection and window period or late stage infection. Therefore HBV DNA NAT in routine blood donor screening can detect HBV DNA in the window period and late stage of infection. This assay provides the reduction of the risk of infection among recipients from blood and the blood product transfusion. In routine blood donor screening laboratory, HBV profile test should be further performed in cases of indeterminate for identifying infection stage and guiding the proper management for the donors.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Busch MP, Lee LL, Satten GA, Henrard DR, Farzadegan H, Nelson KE, et al. Time course of detection of viral and serological markers preceding human immunodeficiency virus type 1 Seroconversion. Transfusion 1995; 35(2): 91-7.
Stramer SL, Caglioti S, Strong DM. NAT of the United States and Canadian blood supply. Transfusion 2000; 40: 1165-8.
Leetrakool N, Fongsatitkul L, Tanan P. Screening donated blood for infectious agents in Maharaj Nakorn Chiang Mai Hospital: Four-year experience of nucleic acid amplication technology (NAT). Bull Chiang Mai Assoc Med Sci 2012; 45: 36-44.
Allain JP. Occult hepatitis B infection: implications in transfusion. Vox Sang 2004; 86: 83-91.
Reesink HW, Engelfriet CP, Henn G, Mayr WR, Delage G, Bernier F, et al. Occult hepatitis B infection in blood donors. Vox Sang 2008; 94:153-66.
Phikulsod S, Oota S, Tirawatnapong T, Sakuldamrongpanich T, Chalermchan W, Louisirirotchanakul S, et al. One-year experience of nucleic acid technology testing for human immunodeficiency virus type 1, hepatitis C virus, and hepatitis B virus in Thai blood donations. Transfusion 2009; 49: 1126-35.
ทัศนีย์ สกุลดำรงค์พานิช, สินีนาฏ อุทา, พัชรากร กรำกระโทก, รัชนี เขื่อนแก้ว, พรทิพย์ รัตจักร, ศิริลักษณ์ เพียกขุนทด, และคณะ. การคัดกรองโลหิตบริจาคด้วยวิธี NAT เพื่อตรวจหาเชื้อ HIV-1, HCV และ HBV โดยศูนย์บริการโลหิตแห่งชาติและภาคบริการโลหิตแห่งชาติสภากาชาดไทย. วารสารโลหิตวิทยาและเวชศาสตร์บริการ โลหิต 2555; 22: 93-100.
Poovorawan Y, Sanpavat S, Chumdermpadetsuk S, Safary A.: Long-term hepatitis B vaccine in infants born to hepatitis B e antigen positive mothers. Arch Dis Child Fetal Neonate Ed 1997; 77(1): F47-51.
Krawczyk A, Hintze C, Ackermann J, Goitowski B, Trippler M, Grüner N, et al. Clinical performance of the novel DiaSorin LIAISON®XL murex: HBsAg Quant, HCV-Ab, HIV-Ab/Ag assays. Clin Virol 2014; 59: 44-9.
Matsubara N, Kusano O, Sugamata Y, Itoh T, Mizuii M, Tanaka J, Yoshizawa H. A Novel Hepatitis B Virus Surface Antigen Immunoassay as Sensitive as Hepatitis B Virus Nucleic Acid Testing in Detecting Early Infection. Transfusion 2009; 49: 585-94
Luksamijarulkul P, Kaepan W, Klamphakorn S. Hepatitis B virus sero-makers, hepatitis C virus antibody and risk behaviors among middle age and older Thai males. Southeast Asian J Trop Med Public Health 2007; 38: 45-52.
Hollinger FB. Hepatitis B virus infection and transfusion medicine:science and the occult. Transfusion 2008; 48: 1001-26.
สิณีนาฏ อุทา, ดวงนภา อินทระสงเคราะห์, รจนา กิมิฬา. ประเมินประสิทธิภาพการตรวจคัดกรองเชื้อไวรัสตับ
อักเสบบี ด้วยน้ำยา Liaison®XL MUREX HBsAg Quantitative ในผู้บริจาคโลหิต. ใน: สิณีนาฏ อุทา, บรรณาธิการ; งานประชุมวิชาการ งานบริการโลหิต ระดับชาติ ครั้งที่ 24; 22-25 มีนาคม 2016; โรงแรมแมนดาริน สามย่าน. กรุงเทพมหานคร; 2016.